Liminatus Pharma (LIMN) Other Accumulated Expenses (2024 - 2026)

Liminatus Pharma has reported Other Accumulated Expenses for 3 years, with the latest figure at $194587.0 in Q1 2026.

• Quarterly Other Accumulated Expenses changed N/A year-over-year to $194587.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $194587.0 (changed N/A YoY) and the FY2025 annual result came in at $209586.0, up 7.34% from the prior year.
• Other Accumulated Expenses declined to $194587.0 in Q1 2026 per LIMN's latest filing, from $209586.0 in the prior quarter.
• Over five years, Other Accumulated Expenses peaked at $209586.0 in Q4 2025 and troughed at $172753.0 in Q2 2025.
• A 3-year average of $190486.4 and a median of $194587.0 in 2026 frame the typical range for Other Accumulated Expenses.
• The widest YoY moves for Other Accumulated Expenses: up 7.34% in 2025, down 7.34% in 2025.
• Over 3 years, Other Accumulated Expenses stood at $195253.0 in 2024, then grew by 7.34% to $209586.0 in 2025, then decreased by 7.16% to $194587.0 in 2026.
• According to Business Quant data, Other Accumulated Expenses over the past three periods registered $194587.0, $209586.0, and $180253.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.